(Q39413134)

11 September 2017

title

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer (English)

1 reference

11 September 2017

1 reference

1 reference

1

T M Beer

1 reference

11 September 2017

W C Pierce

2

1 reference

11 September 2017

B A Lowe

series ordinal

3

1 reference

11 September 2017

W D Henner

series ordinal

4

1 reference

11 September 2017

publication date

1 September 2001

1 reference

11 September 2017

1 reference

11 September 2017

volume

12

1 reference

11 September 2017

issue

9

1 reference

11 September 2017

page(s)

1273-1279

1 reference

11 September 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1012258723075

7 January 2021

Identifiers

DOI

10.1023/A:1012258723075

1 reference

11 September 2017

1 reference